Up-date on Clinical Management of Postherpetic Neuralgia and Mechanism-Based Treatment: New Options in Therapy

J Infect Dis. 2018 Sep 22;218(suppl_2):S120-S126. doi: 10.1093/infdis/jiy381.

Abstract

Patients with postherpetic neuralgia may experience various sensory signs and symptoms of pain. Despite this, the recommendations for medicinal treatment do not differ accordingly. In order to find the appropriate treatment options for postherpetic neuralgia, several attempts have been made in the past. The crucial obstacle to these attempts was insufficient or no subgrouping of patients according to their sensory phenotype, mostly resulting in an unsatisfactory treatment response. Recently, a new concept of retrospective stratification according to the patients' sensory phenotype has been made in a large cohort of pain patients. This new stratification tool allows a predictive validity for treatment response in subgroups of patients and might be of potential value in determining the optimal treatment in postherpetic neuralgia patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine Release Inhibitors / therapeutic use
  • Analgesics / therapeutic use*
  • Antidepressive Agents, Tricyclic / therapeutic use*
  • Botulinum Toxins, Type A / therapeutic use
  • Capsaicin / therapeutic use
  • Cohort Studies
  • Data Interpretation, Statistical*
  • Gabapentin / therapeutic use
  • Humans
  • Neuralgia, Postherpetic / drug therapy*
  • Pregabalin / therapeutic use
  • Sensory System Agents / therapeutic use

Substances

  • Acetylcholine Release Inhibitors
  • Analgesics
  • Antidepressive Agents, Tricyclic
  • Sensory System Agents
  • Pregabalin
  • Gabapentin
  • Botulinum Toxins, Type A
  • Capsaicin